Compare BioNano Genomics Inc (BNGO) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs PepsiCo, Inc. — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while PepsiCo, Inc. trades at $136.4 (market cap $184.87B). The key difference: PepsiCo, Inc. is far larger — about 14005.3× BioNano Genomics Inc's market cap, and PepsiCo, Inc. pays a 4.37% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | PEP | |
|---|---|---|
Market Cap | $13.20M | $184.87B |
Sector | Health | Consumer Staples |
52-Week High | $4.92 | $170.44 |
52-Week Low | $1.09 | $133.81 |
Enterprise Value | $15.81M | $227.37B |
Dividend Yield | — | 4.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
PepsiCo (PEP) trades at $135.75, down 1.98% on the day, with a bearish technical signal and support near $132. The company reported revenue of $93.93B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent news highlights price cuts on snacks like Doritos to address consumer pushback, while analysts expect in-line Q1 2026 results.
The stock offers a dividend yield near 4% and trades below the consensus price target of $159.27, suggesting upside potential. Risks include competitive pressures and execution of the North American turnaround. Wall Street sentiment is mixed, with 33% buy ratings but a majority hold consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
